No Data
No Data
Silo Pharma Announces Results for Its Preclinical Study on SP-26
Express News | Silo Pharma Inc - No Implant-Related Adverse Events Observed in Study
Express News | EXCLUSIVE: Silo Pharma Tells Benzinga 'Successfully Demonstrates Strong Tolerability, Sustained Drug Release and Safety'
Express News | EXCLUSIVE: Silo Pharma Tells Benzinga Co's SP-26 Ketamine Implant Meets All Endpoints In Fibromyalgia Study
Relmada Therapeutics RLMD Phase 2 Data; Silo Pharma SILO Patent
Silo Pharma Files Patent Application With USPTO For SPC-14, Intranasal Compound Exclusively Licensed AD Drug